ClinicalTrials.Veeva
Menu

Find clinical trials for Endometrial Cancer in Cleveland, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Ovarian Cancer
Breast Cancer
Triple Negative Breast Cancer
Ovarian Epithelial Carcinoma
Colorectal Cancer

Endometrial Cancer trials near Cleveland, OH, USA:

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E)

(paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial...

Active, not recruiting
Endometrial Neoplasms
Drug: Carboplatin
Biological: durvalumab

Phase 3

AstraZeneca
AstraZeneca

Cleveland, Ohio, United States and 202 other locations

participants with recurrent or primary advanced (Stage III or IV) endometrial cancer....

Active, not recruiting
Neoplasms
Drug: Paclitaxel
Drug: Carboplatin

Phase 3

Tesaro
Tesaro

Cleveland, Ohio, United States and 168 other locations

in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSigna...

Enrolling
Endometrial Adenocarcinoma
Platinum-resistant Ovarian Cancer
Diagnostic Test: OncoSignature
Drug: ACR-368

Phase 1, Phase 2

Acrivon Therapeutics

Cleveland, Ohio, United States and 66 other locations

first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer...

Enrolling
Endometrial Cancer
Advanced Solid Tumor
Drug: TORL-1-23

Phase 1

TORL Biotherapeutics

Cleveland, Ohio, United States and 4 other locations

The purpose of this trial is to measure the following in participants with solid tumors who receive GEN1047:* The side effects seen with GEN...

Active, not recruiting
Endometrial Cancer, Endometrial Neoplasm
Squamous Non Small Cell Lung Cancer (NSCLC-SCC)
Biological: GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.

Phase 1, Phase 2

Genmab
Genmab

Cleveland, Ohio, United States and 35 other locations

objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by investigator in participants pro ...

Enrolling
Endometrial Cancer
Solid Tumor
Drug: lenvatinib
Biological: pembrolizumab

Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Cleveland, Ohio, United States and 44 other locations

-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer...

Active, not recruiting
Castration-resistant Prostate Cancer
Lower Esophageal Cancer
Drug: cabozantinib
Drug: atezolizumab

Phase 1, Phase 2

Exelixis
Exelixis

Cleveland, Ohio, United States and 123 other locations

tumors....

Enrolling
Endometrial Cancer
Triple Negative Breast Cancer
Biological: NM32-2668

Phase 1

Numab Therapeutics

Cleveland, Ohio, United States and 7 other locations

and clinical antitumor activity of XB002 administered IV q3w alone and in combination with nivolumab to subjects with advanced solid tumors....

Active, not recruiting
Endometrial Cancer
Tissue Factor-Expressing Solid Tumors
Drug: XB002
Drug: Nivolumab

Phase 1

Exelixis
Exelixis

Cleveland, Ohio, United States and 94 other locations

multiple dose levels of PC14586 (INN: rezatapopt) alone (monotherapy) and in combination with pembrolizumab in participants with advanced solid tumors...

Enrolling
Breast Cancer
Advanced Solid Tumor
Drug: PC14586
Drug: pembrolizumab

Phase 1, Phase 2

PMV Pharmaceuticals

Cleveland, Ohio, United States and 65 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems